Dovitinib-RIBOTAC is a novel and potent ribonuclease targeting chimera (RIBOTAC) and RNA degrader with anticancer activity. As a promising new strategy for RNA degradation, RIBOTACs are a new class of small molecules that have the potential to target diverse types of RNAs and may have certain advantages over oligonucleotide-based approaches. RIBOTACs are based on small molecules that selectively bind RNAs, especially RNAs that form intricate secondary and tertiary structures. that stops disease progression in mice engineered to have breast cancer.